ストックスクリーナーアプリを入手
4.93
1.00%
-0.05
前日終値:
$4.98
開ける：
$4.99
24時間の取引高:
1.48M
Relative Volume:
1.69
時価総額：
$387.11M
収益：
$531.00K
当期純損益:
$-99.96M
株価収益率:
-2.2492
EPS:
-2.1919
ネットキャッシュフロー:
$-98.96M
1週間 パフォーマンス:
+17.38%
1か月 パフォーマンス:
+4.67%
6か月 パフォーマンス:
-50.50%
1年 パフォーマンス:
+16.27%
1日の値動き範囲:
$4.92
$5.34
1週間の範囲:
$4.21
$5.34
52週間の値動き範囲:
$3.60
$10.99
Lexeo Therapeutics Inc Stock (LXEO) Company Profile
名前
Lexeo Therapeutics Inc
セクター
電話
(212) 547-9879
住所
345 PARK AVENUE SOUTH, NEW YORK
Compare LXEO vs VRTX, REGN, ARGX, ALNY, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
LXEO
Lexeo Therapeutics Inc
|
4.93 | 387.11M | 531.00K | -99.96M | -98.96M | -2.1919 |
VRTX
Vertex Pharmaceuticals Inc
|
451.63 | 114.63B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
609.94 | 63.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.72 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.09 | 37.13B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
162.99 | 34.65B | 742.00K | -1.37B | -1.07B | -7.0731 |
Lexeo Therapeutics Inc Stock (LXEO) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-12-18 | 開始されました | Raymond James | Strong Buy |
| 2025-11-20 | 開始されました | Cantor Fitzgerald | Overweight |
| 2025-10-15 | 開始されました | Guggenheim | Buy |
| 2025-07-31 | 開始されました | Oppenheimer | Outperform |
| 2024-06-13 | 開始されました | Robert W. Baird | Outperform |
| 2024-06-06 | 開始されました | H.C. Wainwright | Buy |
| 2023-11-28 | 開始されました | Chardan Capital Markets | Buy |
| 2023-11-28 | 開始されました | JP Morgan | Overweight |
| 2023-11-28 | 開始されました | Leerink Partners | Outperform |
| 2023-11-28 | 開始されました | RBC Capital Mkts | Outperform |
| 2023-11-28 | 開始されました | Stifel | Buy |
すべてを表示
Lexeo Therapeutics Inc (LXEO) 最新ニュース
Lexeo Therapeutics Shares Climb Following FDA Breakthrough Therapy Designation - MSN
Lexeo Therapeutics Inc (LXEO) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Lexeo Therapeutics Inc (LXEO) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Lexeo Therapeutics Inc (LXEO) Institutional Confidence - TradingKey
Lexeo Therapeutics Inc (LXEO) Valuation: PE, PB & Fair Value Analysis - TradingKey
Lexeo Therapeutics Inc (LXEO) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Lexeo Therapeutics Inc (LXEO) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Lexeo publishes phase I/II data for gene therapy LX2006 By Investing.com - Investing.com South Africa
Lexeo publishes phase I/II data for gene therapy LX2006 - Investing.com
Lexeo Therapeutics Announces Publication in JAMA Cardiology of Phase I/II Data for LX2006 in Friedreich Ataxia - GlobeNewswire
Lexeo Therapeutics Inc (LXEO) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Lexeo Therapeutics Inc (LXEO) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Why is Lexeo Therapeutics stock gaining Monday? - MSN
Lexeo Therapeutics, Inc. (LXEO) Shareholder/Analyst CallSlideshow (NASDAQ:LXEO) 2026-06-15 - Seeking Alpha
LXEO: Pivotal LX2006 trial in FA finalized, aiming for accelerated approval with strong early data - TradingView
Why Is Lexeo Therapeutics Stock Gaining Monday? - Benzinga
Lexeo Therapeutics Finalizes Study Design for Friedreich Ataxia Gene Therapy - Moomoo
Lexeo Therapeutics (LXEO) Advances Gene Therapy Trial for Friedr - GuruFocus
Lexeo finalizes pivotal trial design for gene therapy LX2006 By Investing.com - Investing.com South Africa
LXEO: Pivotal LX2006 trial in FA to start, targeting LVMI reduction with accelerated approval path - TradingView
Lexeo finalizes pivotal trial design for gene therapy LX2006 - Investing.com UK
2 Stocks To Watch Today Following Clinical Trial Updates - RTTNews
Lexeo Therapeutics Finalizes SUNRISE-FA 2 Pivotal Trial Protocol And Statistical Analysis Plan For LX2006 Gene Therapy In Friedreich Ataxia - marketscreener.com
Lexeo Advances Pivotal LX2006 Trial for FA Cardiomyopathy - TipRanks
Lexeo finalizes SUNRISE-FA 2 pivotal design for LX2006; topline data due 2H 2027, BLA targeted 1H 2028 - TradingView
Lexeo Therapeutics Announces Regulatory Update And Registrational Trial Design For LX2006 Gene Therapy In Friedreich Ataxia - TradingView
Lexeo Therapeutics Advances SUNRISE-FA 2 Pivotal Trial for Gene Therapy LX2006 in Friedreich Ataxia Cardiomyopathy - Quiver Quantitative
LXEO: Pivotal trial for LX2006 in Friedreich ataxia set for Q2 2026, targeting BLA in 2028 - TradingView
LXEO: Pivotal LX2006 study set for Q2 2026, aiming for accelerated approval and BLA in 1H 2028 - TradingView
Lexeo Therapeutics (Nasdaq: LXEO) maps LX2006 pivotal trial, 2027 data and 2028 BLA bid - Stock Titan
Gene therapy trial aims to tackle Friedreich ataxia heart damage - Stock Titan
Lexeo Therapeutics Announces Regulatory Update and - GlobeNewswire
Lexeo Therapeutics Rallies 4% as Bullish Momentum Builds Above Key SupportBear Flag - newsline.com
LEXEO THERAPEUTICS INC (LXEO) Stock Chart - ChartMill
Lexeo Therapeutics (LXEO) Edges Higher, Holds Above Key Support After Modest GainPairs Trade - newsline.com
Cantor Fitzgerald Initiates Coverage of Lexeo Therapeutics (LXEO) with Overweight Recommendation - MSN
LXEO News | LEXEO THERAPEUTICS INC (NASDAQ:LXEO) - ChartMill
Here's Why We're Watching Lexeo Therapeutics' (NASDAQ:LXEO) Cash Burn Situation - Sahm
Lexeo Therapeutics (LXEO) Slips 2.29% as Stock Tests Key Support LevelsRSI Overbought Alerts - The Legal Advocate
Lexeo Therapeutics Q1 2026 Earnings: EPS Beat on Lower Operating CostsProfit Announcement - Newser
Lexeo Therapeutics (LXEO) Sees Mild Gains as Stock Holds Above Key SupportATR Trailing Stop - Newser
Top Executive Makes Notable Move in Lexeo Therapeutics Stock - TipRanks
Lexeo (LXEO) COO sells 1,302 shares in tax-related stock sale - Stock Titan
Lexeo Therapeutics (LXEO) CEO sells 3,342 shares in tax-related RSU transaction - Stock Titan
Lexeo Therapeutics (LXEO) Climbs +10.49% — Resistance at $5.20 in Focus 2026-05-20Retail Driven Moves - Newser
Lexeo Therapeutics to Participate in the 2026 RBC Capital Markets Global Healthcare Conference - Caledonian Record
LXEO (NASDAQ:LXEO) Rule 144 notice: 3,342 vested shares; prior sale 10,173 - Stock Titan
LXEO (NASDAQ: LXEO) lists restricted stock vesting; Form 144 shows past sale - Stock Titan
LXEO (NASDAQ: LXEO) insider sale notice — 1,595 vested shares - Stock Titan
4 spaces primed for the next wave of gene therapies - BioSpace
Paradigm BioCapital holds 6.18M Lexeo shares (LXEO); 8.3% stake reported - Stock Titan
Lexeo Therapeutics Inc (LXEO) 財務データ
収益
当期純利益
現金流量
EPS
0.74%
1.44%
大文字化:
|
ボリューム (24 時間):